Neumora Therapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2022 Dec2023 Dec2024
Operating Activities
Net Income -130.90M-235.93M-243.79M
Share-based Compensation 8.30M17.24M39.99M
Gains from Investment Securities 8.87M0.19M0.47M
Cash from Operations -114.90M-163.28M-182.94M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) 0.60M0.70M0.63M
Change in Working Capital
Change in Account Payables -1.25M-0.58M2.87M
Change in Accured Expenses -1.62M6.49M7.24M
Investing Activities
Capital Expenditures 0.51M0.12M
Change in Acquisitions & Divestments 71.87M178.17M
Cash from Investing Activities -168.01M64.39M-70.56M
Financing Activities
Other financing activities 0.74M3.80M
Change in Capital Stock
Shares Issued 2.66M232.56M7.48M
Preferred Shares Issued 112.22M
Misc.
Cash from Financing Activities 115.74M231.94M21.60M
Change in Cash -167.17M133.04M-231.89M
Free Cash Flow -115.41M-163.40M-182.94M
Net Cash Flow -167.17M133.04M-231.89M